Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2021-11-18 00:00:00 ET · period of report 2021-11-16 · accession 0001708138-21-000088 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-18 | 2021-11-17 | REGN | Landry Robert E | EVP Fin CFO | S - Sale+OE | $645.08 | -681 | 26.0K | -3% | -$439.3K |
| D | 2021-11-18 | 2021-11-16 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $651.97 | -3,069 | 26.7K | -10% | -$2.00M |
| D | 2021-11-18 | 2021-11-16 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $399.66 | +3,750 | 29.7K | +14% | +$1.50M |
| D | 2021-11-18 | 2021-11-16 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -3,750 | 21.2K | -15% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-17 | S | D | 681 | $645.08 | 25,986 | D | — | — | |
| 2 | Common | Common Stock | 2021-11-16 | F | D | 3,069 | $651.97 | 26,667 | D | — | — | |
| 3 | Common | Common Stock | 2021-11-16 | M | A | 3,750 | $399.66 | 29,736 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-11-16 | M | D | 3,750 | $0.00 | 21,250 | D | $399.66 · — to 2024-12-16 | 3,750 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |